Eli Lilly announced promising results from a mid-stage clinical trial, revealing that its experimental combination therapy produced greater weight loss than its leading drug, tirzepatide, when administered alone. The innovative regimen, combining the new drug eloralintide and a low dose of tirzepatide, demonstrated effectiveness in patients with obesity and Type 2 diabetes—groups that often face substantial challenges in weight management. Lilly plans to initiate Phase 3 trials for this combination by the end of 2026.
The combination therapy includes eloralintide, which focuses on the hormone amylin to help regulate appetite, along with tirzepatide, which targets two gut hormones, GLP-1 and GIP. In the 48-week trial, patients receiving the highest dose of the combination lost an average of 54 pounds, equating to 23.3% of their body weight. In contrast, those on a standalone 15-mg dose of tirzepatide lost an average of 34.4 pounds, or 14.8% of their weight.
Although the results highlighted significant weight loss, they also raised concerns regarding tolerability; discontinuation rates due to side effects were higher for the combination treatment compared to tirzepatide alone. Ken Custer, Lilly’s president of Cardiometabolic Health, stated that the findings would inform dosing adjustments in forthcoming trials, contributing to a more favorable balance between efficacy and tolerability.
Lilly’s efforts to develop a co-formulated version of the two drugs aim to simplify treatment for patients. Analysts view this combination as a viable competitor to other obesity therapies, potentially offering a robust option tailored to patients who have not experienced success with existing treatments.
Why this story matters
Key takeaway
Opposing viewpoint
